GPC3 CAR-T Cells With Orthogonal IL2 Signaling for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies for solid tumors, particularly those targeting GPC3, face challenges such as rapid loss of function, significant toxicity from high-dose IL2 administration, and high relapse rates, limiting their effectiveness and safety.
Innovation Solution
Development of GPC3 CAR-T cells engineered to express an orthogonal CD122 receptor, combined with a selective orthogonal IL2 ligand, enabling selective expansion and prolonged persistence within the body, and intratumoral infiltration, using a combination of genetic modification and targeted activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose IL2 is administered to support CAR-T cell efficacy, then therapeutic effectiveness is improved, but toxicity increases significantly
Solution Approach 1:
The patent introduces an orthogonal IL2 receptor system as an intermediary mechanism. The CAR-T cells are engineered to express a modified IL2 receptor (CD122) that selectively binds to a engineered IL2 variant, creating a dedicated signaling pathway that bypasses the toxic effects of systemic high-dose IL2 administration while maintaining therapeutic efficacy through selective cell activation and expansion
Solution Approach 2:
The patent modifies the IL2 receptor parameters by engineering a variant CD122 with altered binding specificity. This parameter change allows the receptor to selectively bind to the engineered IL2 variant rather than endogenous IL2, enabling selective activation of CAR-T cells without triggering the toxic immune responses associated with high-dose IL2 therapy
2Reliability
If CAR-T cells are administered to treat solid tumors, then initial anti-tumor activity is achieved, but rapid loss of function occurs leading to relapse
Solution Approach 1:
The orthogonal IL2/CD122 system acts as a mediator that sustains CAR-T cell persistence. By providing a selective survival and expansion signal through the engineered receptor-ligand interaction, the system maintains therapeutic cell populations in the tumor microenvironment without relying on toxic high-dose IL2 support
Solution Approach 2:
The engineered CAR-T cells equipped with orthogonal CD122 receptors can autonomously respond to administered engineered IL2 variant, enabling self-expansion and self-sustenance within the tumor microenvironment. This self-service capability allows prolonged persistence and sustained anti-tumor activity without continuous external intervention
Data Source
AI summary
Engineered T cells are provided that express (a) a chimeric antigen receptor wherein the antigen binding domain of the CAR binds to human GPC3 (“a GPC-CAR”); and (b) an orthogonal receptor. Also provided are methods of making and using such engineered T cells.